Avricore Health Inc. (TSE:AVCR)
:AVCR
Want to see TSE:AVCR full AI Analyst Report?
Top Page
Avricore Health
(AVCR)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.05
▲(8.00% Upside)
Action:Reiterated
Date:05/21/26
The score is primarily constrained by weak financial performance durability (2025 revenue contraction, larger losses, and renewed cash burn) despite prior margin improvement and low debt. Technicals add further pressure as the stock trades below major moving averages with negative MACD. Valuation remains difficult to support due to ongoing losses and no dividend.
Positive Factors
Conservative Balance Sheet
Minimal leverage reduces solvency and refinancing risk over the medium term, giving management flexibility to fund operations or strategic pushes without heavy interest burdens. For a company with volatile cash flow, low debt materially lowers probability of distress and preserves optionality.
Negative Factors
Sharp 2025 Revenue Contraction
A pronounced revenue collapse in 2025 undermines the durability of prior growth and raises questions about customer retention, program demand, or contract continuity. Persistent top-line volatility makes forecasting cash flow and achieving scale economics materially harder over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Minimal leverage reduces solvency and refinancing risk over the medium term, giving management flexibility to fund operations or strategic pushes without heavy interest burdens. For a company with volatile cash flow, low debt materially lowers probability of distress and preserves optionality.
Read all positive factors
Avricore Health (AVCR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.57M
Dividend YieldN/A
Average Volume (3M)51.37K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth-88.84%
EPS Growth-177.27%
CountryCA
Employees26
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding101,289,665
10 Day Avg. Volume29,762
30 Day Avg. Volume51,367
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avricore Health Business Overview & Revenue Model
Company Description
Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a lab-accurate point of care testing platform for pharmacy. The company has strategic partnerships with Shoppers Drug Marts a...
How the Company Makes Money
Avricore Health makes money primarily by providing point-of-care testing programs and associated technology/services to pharmacies and other healthcare providers. Revenue is generated from (a) fees tied to delivering testing services in participat...
Avricore Health Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 533.88K | 4.79M | 3.49M | 1.77M | 122.81K |
| Gross Profit | 236.33K | 1.88M | 1.20M | 456.79K | 30.52K |
| EBITDA | -1.23M | -208.44K | -275.14K | -629.76K | -1.64M |
| Net Income | -1.86M | -668.98K | -701.22K | -818.23K | -1.71M |
Balance Sheet | |||||
| Total Assets | 563.13K | 2.30M | 2.54M | 2.57M | 2.28M |
| Cash, Cash Equivalents and Short-Term Investments | 237.92K | 1.14M | 286.57K | 630.53K | 2.01M |
| Total Debt | 0.00 | 0.00 | 40.00K | 40.00K | 40.00K |
| Total Liabilities | 173.56K | 330.82K | 529.22K | 604.89K | 84.48K |
| Stockholders Equity | 389.56K | 1.97M | 2.01M | 1.96M | 2.20M |
Cash Flow | |||||
| Free Cash Flow | -878.43K | 799.27K | -386.46K | -1.64M | -1.37M |
| Operating Cash Flow | -789.93K | 1.00M | 660.40K | -437.83K | -1.23M |
| Investing Cash Flow | -114.36K | -205.35K | -1.05M | -1.21M | -140.36K |
| Financing Cash Flow | 0.00 | 56.60K | 42.50K | 253.88K | 3.08M |
Avricore Health Technical Analysis
Negative
0.05
Price Trends
0.07
Negative
0.07
Negative
0.06
Negative
Market Momentum
>-0.01
Positive
40.90
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCR, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.90 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AVCR.
Avricore Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$63.05M | -32.47 | ― | ― | -40.80% | 22.49% | |
47 Neutral | C$5.02M | -2.38 | -9999.00% | ― | ― | 18.13% | |
45 Neutral | C$5.57M | -2.72 | -95.29% | ― | -88.84% | -177.27% | |
45 Neutral | C$5.48M | -2.47 | ― | ― | ― | 85.58% |
* Healthcare Sector Average
TSE:AVCR
Avricore Health
0.06
<0.01
9.09%
TSE:BUX
BioMark Diagnostics
0.60
0.30
100.00%
TSE:TELO
Telo Genomics Corp
0.06
-0.03
-33.33%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:NARA
PanGenomic Health, Inc. Class A
0.40
0.22
122.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.